MedPath

SciTech Development Appoints John Chapman to Strategic Advisory Board

• SciTech Development has appointed John Chapman, formerly of KPMG, to its Strategic Advisory Board as Senior Financial Advisor. • Chapman's expertise includes financial strategy, SEC reporting, IPOs, and M&A, bringing significant value to SciTech's financial operations. • SciTech is currently in Phase 1 clinical trials with ST-001 nanoFenretinide for T-Cell Non-Hodgkin Lymphoma. • Chapman expressed enthusiasm for contributing to SciTech's mission of bringing innovative cancer treatments to market.

SciTech Development, Inc., a clinical-stage biotechnology company focused on innovative cancer therapeutics, has announced the appointment of John Chapman, CPA, to its Strategic Advisory Board as Senior Financial Advisor. Chapman's extensive background in financial strategy and the pharmaceutical sector is expected to guide SciTech's growth and innovation.
Chapman's Background
John Chapman was a Senior Partner at KPMG, where he served on the Board of Directors for KPMG LLP and KPMG Americas. His career included roles as Global Chair of KPMG's Pharmaceuticals Practice and Global Lead Partner, working with multinational corporations such as Pfizer and Hoechst AG. He has advised C-suite executives on complex financial matters, including SEC reporting, initial public offerings, and mergers and acquisitions. Chapman is also recognized as a Financial Expert by the SEC.
Chapman's Perspective
"I am delighted to be joining SciTech Development as a part of their Strategic Advisory Board," said Chapman. "SciTech has an exceptionally talented management team, along with an impressive medical and strategic advisory board. The company's patented lead drug, ST-001 nanoFenretinide, has the potential to revolutionize cancer care and bring hope to cancer patients. I am eager to contribute to SciTech's efforts to bring innovative, life-saving treatments to market."
ST-001 nanoFenretinide
ST-001 is a patented, aqueous suspension of nanoparticles containing fenretinide within phospholipid bilayers, designed to enhance bioavailability, delivery, and efficacy for cancer treatment. SciTech is currently in Phase 1 clinical trials for the treatment of T-Cell Non-Hodgkin Lymphoma.
Leadership Insight
"With his deep knowledge of the pharmaceutical industry and experience in strategic financial advisory roles, John's insights will be invaluable as SciTech Development advances its lead drug, ST-001, and its cutting-edge drug delivery platform," said Earle Holsapple, CEO of SciTech Development. "John's appointment underscores the company's focus on sustainable financial growth and innovation in the industry."
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Highlighted Clinical Trials

Related Topics

Yaqrit Appoints Troels Jordansen as CEO to Spearhead Late-Stage Clinical Development

Yaqrit has appointed Troels Jordansen as its new CEO to advance the clinical development and commercial strategy for its liver disease treatments.
Jordansen brings extensive experience in fundraising and business development, having raised over €200 million for public and private companies.

Sling Therapeutics Appoints Andrew Guggenhime to Board as Linsitinib Advances in Phase 2b for TED

Sling Therapeutics appointed Andrew Guggenhime to its Board of Directors, leveraging his extensive biopharma experience to advance clinical programs.
Guggenhime's financial expertise will support Sling as it anticipates key milestones for linsitinib, an oral treatment for thyroid eye disease (TED).

Applied Therapeutics Announces Leadership Changes and Strategic Updates

Applied Therapeutics appoints John H. Johnson as Executive Chairman, leveraging his extensive experience to drive growth and value creation.
Les Funtleyder steps in as Interim CEO while maintaining his role as CFO, ensuring continuity and focus on pipeline advancement.

VectorY Therapeutics Appoints Jim Scibetta as CEO, Advances ALS Program

VectorY Therapeutics has appointed Jim Scibetta as its new CEO, succeeding Sander van Deventer, who will transition to President of R&D.
The company's lead program, VTx-002, a vectorized antibody targeting TDP-43 for ALS, is advancing into IND-enabling studies following positive FDA feedback.

Summit Therapeutics' Phase 3 HARMONi Trial Poised for Mid-2025 Readout in Duchenne Muscular Dystrophy

Summit Therapeutics' HARMONi Phase 3 trial is expected to release topline results in mid-2025, potentially driving significant stock movement.
The trial investigates the efficacy of ezutromid, an oral small molecule, in treating Duchenne Muscular Dystrophy (DMD) by upregulating dystrophin.

Nanoscope Therapeutics Enhances Vision Restoration Therapy with CatCh Technology License

Nanoscope Therapeutics has licensed the CatCh technology from Max Planck Innovation to boost the light sensitivity of its MCO-010 gene therapy.
MCO-010, a tri-protein fusion complex, targets inherited retinal degenerative diseases like retinitis pigmentosa and Stargardt disease, showing promise in clinical studies.

Ananda Developments Appoints Professor Marie Fallon to Scientific Advisory Board

Ananda Developments has appointed Professor Marie Fallon to its Scientific Advisory Board (SAB) to enhance its research and clinical development of CBD-based therapies.
Professor Fallon, an expert in palliative medicine and neuropathy, will provide technical advice and guidance to Ananda's scientific activities.

Resiniferatoxin Receives FDA Breakthrough Therapy Designation for Osteoarthritis Pain

Grünenthal's resiniferatoxin (RTX), a non-opioid therapy, has been granted Breakthrough Therapy Designation by the FDA for knee osteoarthritis pain.
The FDA's decision is based on preliminary clinical evidence suggesting RTX may offer substantial improvement over existing therapies.

Summit Therapeutics' Phase III Trial Bests Merck's Keytruda in Lung Cancer

Summit Therapeutics' SMT-i100 demonstrated superior efficacy compared to Keytruda in a Phase III trial for non-small cell lung cancer (NSCLC).
The study highlighted SMT-i100's potential as a novel therapeutic option, particularly in patients with PD-L1 negative or low expressing tumors.

VasoRx's Lipid Nanoparticle Drug Delivery System Targets TGFβ-Related Diseases

VasoRx, a Yale-backed startup, is developing a lipid nanoparticle drug delivery system for targeted drug delivery, potentially reducing toxicity and side effects.
The technology focuses on diseases correlated with the transforming growth factor beta (TGFβ) superfamily, including cardiovascular diseases and inherited disorders.

Reference News

[1]
SciTech Development Welcomes John Chapman to the Strategic Advisory Board as Senior ...
kilgorenewsherald.com · Dec 8, 2024

SciTech Development adds John Chapman, CPA, to its Strategic Advisory Board as Senior Financial Advisor, leveraging his ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy